Anti-Angiogenesis Compound Targets Laminin Receptor in Cancer Cells

Back to all technologies
Download as PDF
2017-FIGU-67894
Laminin receptor (37/67 LR) is a membrane protein when over-expressed can promote metastasis of cancer cells. This is due to the ability of 37/67 LR to promote blood vessel formation in tumors in a process called angiogenesis. Pigment epithelium-derived factor (PEDF) is an endogenous protein that can bind to 37/67 LR to inhibit angiogenesis. PEDF is a viable therapy for cancer patients but due to it being an endogenous protein there are enzymes present in the body that degrade it. As well as, peptide formulation for drug delivery is difficult due to protein stability.

Researchers at Purdue University have developed a small molecule that elicits a similar response as PEDF when it binds to 37/67 LR. Upon binding to 37/67 LR, the hit compound, C3, modulated an anti-angiogenesis pathway that inhibited prostate cancer cell viability, proliferation, and migration. Due to C3 being a small molecule, it did not bind to PEDF proteolytic enzymes, thus, bypassing PEDF degradation process which could result in longer duration of action. C3 is a promising hit compound which has potential for future development as a lead compound for prostate cancer treatment.

Advantages:
- Anti-tumor
- Anti-angiogenesis
- Bypass proteolytic degradation

Potential Applications:
- Prostate cancer therapy
- Chemotherapy

Related Publication: Charles Samuel Umbaugh Et al., A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model
Oncotarget, 2018, Vol. 9, (No. 5), pp: 5958-5978
Aug 27, 2018
Utility Patent
United States
(None)
(None)

Aug 29, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org